Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-23-021576
Filing Date
2023-03-30
Accepted
2023-03-30 11:02:42
Documents
2
Period of Report
2023-03-29

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2148
2 POA DOCUMENT poa.txt EX-24 4050
  Complete submission text file 0001209191-23-021576.txt   7765
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 91 JAMES AVENUE ATHERTON CA 94027
Business Address
KING THOMAS BRAXTON (Reporting) CIK: 0001279309 (see all company filings)

Type: 3 | Act: 34 | File No.: 033-80623 | Film No.: 23777837